The Parkinson Patient: More than Just Motor
Manifestations
Module 1: Mood dysfunction
Module 2: Hallucinations and dementia
Module 3: Sleep dysfunction and daytime somnolence
Module 4: Autonomic dysfunction
Introduction
In advanced Parkinson disease there is overlap in the management of a wide range of autonomic dysfunctions and other problems (e.g., sleep disorders, daytime somnolence, depression, dementia) between the primary care physician and movement disorder specialist. James Brownlee, MD Chairman and Professor, Department of Family Medicine, University of South Florida College of Medicine, and Tanya Simuni, MD, Associate Professor of Neurology and Director of the Parkinson Disease and Movement Disorder Center at Northwestern University Feinberg School of Medicine provide a insightful perspective on these nonmotor complications in the treatment of the Parkinson disease patient.
Intended Audience
This continuing medical education program is intended for primary care physicians and other healthcare professionals who manage patients with Parkinson disease.
Educational Objectives
After completing this activity, participants should be better able to:
- Recognize the occurrence of depression and other mood disorders in the Parkinson disease patient.
- Consider the management of dementia in later stages of Parkinson disease as well recognizing drug/disease- related hallucinations.
- Recognize the problems of sleep disruption in the Parkinson disease patient and problems of daytime somnolence
- Assess the impact of overall autonomic dysfunction on overall disease management
Information on CME credit
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The American Medical Association designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Instructions for CME credit
This online enduring material is presented as a video webcast, featuring a clinical exchange, with attendant slide presentation. To receive credit, please view all of the presentations of this CME activity and evaluate the content presented. Complete both the pre- and post-test and activity evaluation.
The estimated time to complete this activity, including pre-test, review of the materials, and self-assessment and evaluation is 1 hour.
Principal Faculty
H. James Brownlee, Jr., MD, Author/Presenter
Chairman and Professor
Department of Family Medicine
University of South Florida College of Medicine
Tampa, FL
William J. Weiner, MD, Planning Committee Chair, Content Reviewer
Professor of Neurology
Chair, Department of Neurology
Director, Maryland Parkinson Disease and Movement Disorder Center
University of Maryland School of Medicine
Baltimore, MD
Shobha S. Rao, MD, Planning Committee, Content Reviewer
Assistant Professor
Family and Community Medicine
Departments of Geriatric and Family Medicine
University of Texas Southwestern Medical School
Dallas, TX
Kathleen M. Shannon, MD, Planning Committee, Content Reviewer
Associate Professor, Neurological Sciences
Department of Neurology
Rush Movements Disorders Group
Rush-Presbyterian-St. Luke's Medical Center
Rush Medical College
Chicago, IL
Tanya Simuni, MD, Author/Presenter
Associate Professor of Neurology
Director, Parkinson Disease and Movement Disorder Center
Northwestern University Medical School
Chicago, IL
Oksana Suchowersky, MD, FRCPC, FCCMG, Planning Committee, Content Reviewer
Professor and Head
Department of Medical Genetics
Director, Movement Disorders Program
University of Calgary
Calgary, AB, Canada
R. Mark Evans, PhD, Planning Committee
Director, Healthcare Education Products and Standards
American Medical Association
Chicago, IL
Kristi Eidsvoog, PhD, Planning Committee
Content Manager
MedEd Architects, LLC
Chicago, IL
Patti Fitzgerald, Planning Committee
Manager, Product Development, Healthcare Education Products and Standards
American Medical Association
Chicago, IL
Disclosure Policy
In order to assure the highest quality of CME programming, and to comply with the ACCME Standards for Commercial Support, the AMA requires that all faculty and planning committee members disclose relevant financial relationships with any commercial or proprietary entity producing health care goods or services relevant to the content being presented. We therefore obtain a completed disclosure and attestation form to inform the participant of any pertinent relationships disclosed, provided here.
These materials have been peer-reviewed by the members of the CME Advisory Board and the AMA Editorial Board to ensure the continued scientific accuracy and medical relevance of information presented and its independence from commercial bias. The AMA has control over all final content.
Dr. Brownlee: Nothing relevant to disclose
Dr. Rao: Nothing relevant to disclose
Dr. Shannon: Research Support, Kyowa, Schwarz, Teva, Schering/Titan; Consultant, Valeant, Prestwick
Dr. Simuni: Consultant, GlaxoSmithKline, Boehringer-Ingleheim, Medtronic, Valeant, Vernalis, Teva, Novartis
Dr. Suchowersky: Speaker's Bureau, Teva, Novartis; Advisory Board, Teva, Novartis
Dr. Weiner: Advisory Board, Novartis; Research Support, Boehringer-Ingelheim, Teva; Speaker's Bureau, Teva
Dr. Evans: Nothing relevant to disclose
Dr. Eidsvoog: Nothing relevant to disclose
Ms. Fitzgerald: Nothing relevant to disclose
Acknowledgement of Support
This CME publication was supported through an independent education grant from Teva Neuroscience and produced in accordance with the AMA Standards for Industry-Supported Multimedia Continuing Medical Education and Other Communications.
Term of approval
Original Release Date- June 2008
Date of the Most Recent Review- July 2009
Expiration Date- December 2010
